

In der Diskussion:

Können die Alzheimer- und Parkinson-Krankheit durch selbstreplizierende Proteinpartikel übertragen werden?

- 1) Minati L, Edginton T, Bruzzone MG, Giaccone G
(2009) Current concepts in Alzheimer's disease: a multidisciplinary review.
Am J Alzheimers Dis Other Demen **24**:95-121.
- 2) Iqbal K, Liu F, Gong CX, Grundke-Iqbal I
(2010) Tau in Alzheimer disease and related tauopathies.
Curr Alzheimer Res **7**:656-664.
- 3) Davie CA
(2008) A review of Parkinson's disease.
Br Med Bull **86**:109-127.
- 4) Parchi P, Saverioni D
(2012) Molecular pathology, classification, and diagnosis of sporadic human prion disease variants.
Folia Neuropathol **50**:20-45.
- 5) Sikorska B, Knight R, Ironside JW, Liberski PP
(2012) Creutzfeldt-Jakob disease.
Adv Exp Med Biol **724**:76-90.
- 6) Prusiner SB (1982)
Novel proteinaceous infectious particles cause scrapie.
Science **216**:136-144.
- 7) Prusiner SB
(1998) Prions.
Proc Natl Acad Sci USA **95**:13363-13383.
- 8) Chiti F, Dobson CM
(2006) Protein misfolding, functional amyloid, and human disease.
Annu Rev Biochem **75**:333-366.
- 9) Brown P, Cervenakova L
(2005) A prion lexicon (out of control).
Lancet **365**:122.
- 10) Come JH, Fraser PE, Lansbury PT
(1993) A kinetic model for amyloid formation in the prion diseases: importance of seeding.
Proc Natl Acad Sci USA **90**:5959-5963.
- 11) Soto C
(2011) Prion hypothesis: the end of the controversy?
Trends Biochem Sci **36**:151-158.
- 12) Moreno JA, Radford H, Peretti D, et al.
(2012) Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration.
Nature **485**:507-511.
- 13) Brown P, Brandel JP, Sato T, et al.
(2012) Iatrogenic Creutzfeldt-Jakob disease, final assessment.
Emerg Infect Dis **18**:901-907.

- 14) Beekes M
(2010) Die variante Creutzfeldt-Jakob-Krankheit (vCJK). *Epidemiologie und Schutzmaßnahmen gegen eine Übertragung von Mensch zu Mensch*.
Bundesgesundheitsbl/Gesundheitsforsch/Gesundheitsschutz **53**:597-606.
- 15) Peden A, McCardle L, Head MW, et al.
(2010) Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia.
Haemophilia **16**:296-304
- 16) Task Force vCJK
(2002) Die Variante der Creutzfeldt-Jakob-Krankheit (vCJK). *Epidemiologie, Erkennung, Diagnostik und Prävention unter besonderer Berücksichtigung der Risikominimierung einer iatrogenen Übertragung durch Medizinprodukte, insbesondere chirurgische Instrumente - Abschlussbericht der Task Force vCJK zu diesem Thema*.
Bundesgesundheitsbl/Gesundheitsforsch/Gesundheitsschutz **45**:376-394.
- 17) Arbeitsgruppe "Gesamtstrategie Blutversorgung angesichts vCJK"
(2006) Bericht der Arbeitsgruppe "Gesamtstrategie Blutversorgung angesichts vCJK". http://www.pei.de/SharedDocs/Downloads/blut/gesamtstrategie/gesamtstrategie-bericht-2006.pdf?__blob=publicationFile&v=1 (Letzter Zugriff: 28.02.2013).
- 18) Beekes M, McBride PA
(2007) The spread of prions through the body in naturally acquired transmissible spongiform encephalopathies.
FEBS J **264**:588-605.
- 19) Brundin P, Melki R, Kopito R
(2010) Prion-like transmission of protein aggregates in neurodegenerative diseases.
Nat Rev Mol Cell Biol **11**:301-307.
- 20) Lee SJ, Lim HS, Masliah E, Lee HJ
(2011) Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives.
Neurosci Res **70**:339-348.
- 21) Jucker M, Walker LC
(2011) Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.
Ann Neurol **70**:532-540.
- 22) Polymenidou M, Cleveland DW
(2011) The seeds of neurodegeneration: prion-like spreading in ALS.
Cell **147**:498-508.
- 23) Guest WC, Silverman JM, Pokrishevsky E, O'Neill MA, Grad LI, Cashman NR
(2011) Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit.
J Toxicol Environ Health A **74**:1433-1459.
- 24) Polymenidou M, Cleveland DW
(2012) Prion-like spread of protein aggregates in neurodegeneration.
J Exp Med **209**:889-893.
- 25) Arbeitskreis Blut des Bundesministeriums für Gesundheit (2012)
Sicherheit von Blut und Blutprodukten angesichts aktueller Berichte über die Übertragbarkeit der Alzheimer-Krankheit im Tierexperiment.
http://www.rki.de/DE/Content/Kommissionen/AK_Blut/Stellungnahmen/download/stAlzheimer_Erlaeuterungen.pdf?__blob=publicationFile (Letzter Zugriff: 28.02.2013).
- 26) Olanow CW, Brundin P (2013)
Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Mov Disord **28**:31-40.

- 27) Walker L, Levine H, Jucker M
(2006) Koch's postulates and infectious proteins.
Acta Neuropathol **112**:1-4.
- 28) Kane MD, Lipinski WJ, Callahan MJ, et al.
(2000) Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice.
J Neurosci **20**:3606-3611.
- 29) Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al.
(2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host.
Science **313**:1781-1784.
- 30) Eisele YS, Bolmont T, Heikenwalder M, et al.
(2009) Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation.
Proc Natl Acad Sci U S A **106**:12926-12931.
- 31) Eisele YS, Obermuller U, Heilbronner G, et al.
(2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis.
Science **330**:980-982.
- 32) Stöhr J, Watts JC, Mensinger ZL, et al.
(2012) Purified and synthetic Alzheimer's amyloid beta (Abeta) prions.
Proc Natl Acad Sci U S A **109**:11025-11030.
- 33) Baker HF, Ridley RM, Duchon LW, Crow TJ, Bruton CJ
(1994) Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy.
MolNeurobiol **8**:25-39.
- 34) Maclean CJ, Baker HF, Ridley RM, Mori H
(2000) Naturally occurring and experimentally induced beta-amyloid deposits in the brains of marmosets (*Callithrix jacchus*).
J Neural Transm **107**:799-814.
- 35) Ridley RM, Baker HF, Windle CP, Cummings RM
(2006) Very long term studies of the seeding of beta-amyloidosis in primates.
J Neural Transm **113**:1243-1251.
- 36) Brown P, Gibbs CJ, Jr., Rodgers-Johnson P, et al.
(1994) Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease.
AnnNeurol **35**:513-529.
- 37) Irwin DJ, Abrams JY, Schonberger LB, et al.
(2013) Evaluation of Potential Infectivity of Alzheimer and Parkinson Disease Proteins in Recipients of Cadaver-Derived Human Growth Hormone.
AMA Neurol:1-7.
- 38) Caughey B, Baron GS, Chesebro B, Jeffrey M
(2009) Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.
Annu Rev Biochem **78**:177-204.
- 39) Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C (2011)
De novo induction of amyloid-b deposition in vivo.
Mol Psychiatry **17**:1347-1353.
- 40) Rosen RF, Fritz JJ, Dooyema J, et al.
(2012) Exogenous seeding of cerebral beta-amyloid deposition in betaAPP-transgenic rats.
J Neurochem **120**:660-666.

- 41) Ashe KH, Aguzzi A
(2013) Prions, prionoids and pathogenic proteins in Alzheimer disease.
Prion **7**:55-59.
- 42) Soto C, Salvadores-Bersezio N, Moreno-Gonzalez I, et al.
(2011) Transmission of Alzheimer Disease and Type 2 Diabetes by a prion mechanism.
Prion 5 Supplement April/May/June **2011**:14.
- 43) Duran-Aniotz C, Morales R, Estrada L, Urayama A, Morales-Scheiing D, Soto C
(2012) Induction of amyloid deposition and memory impairments in animal models of Alzheimer disease by blood transfusion.
Prion 6 Supplement April/May/June **2012**:79.
- 44) Clavaguera F, Bolmont T, Crowther RA, et al.
(2009) Transmission and spreading of tauopathy in transgenic mouse brain.
Nat Cell Biol **11**:909-913.
- 45) Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM
(2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.
Neuron **34**:521-533.
- 46) Mougenot AL, Nicot S, Bencsik A, et al.
(2011) Prion-like acceleration of a synucleinopathy in a transgenic mouse model.
Neurobiol Aging **33**:2225-2228.
- 47) Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM
(2012) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice.
J Exp Med **209**:975-986.
- 48) Luk KC, Kehm V, Carroll J, et al.
(2012) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.
Science **338**:949-953.
- 49) Masuda-Suzukake M, Nonaka T, Hosokawa M, et al.
(2013) Prion-like spreading of pathological alpha-synuclein in brain.
Brain (Epub ahead of print).
- 50) Snowdon DA
(1997) Aging and Alzheimer's disease: lessons from the Nun Study.
Gerontologist **37**:150-156.
- 51) Snowdon DA
(2003) Healthy aging and dementia: findings from the Nun Study.
Ann Intern Med **139**:450-454.
- 52) Tyas SL, Snowdon DA, Desrosiers MF, Riley KP, Markesbery WR
(2007) Healthy ageing in the Nun Study: definition and neuropathologic correlates.
Age Ageing **36**:650-655.
- 53) Rafalowska J, Barcikowska M, Wen GY, Wisniewski HM
(1988) Laminar distribution of neuritic plaques in normal aging, Alzheimer's disease and Down's syndrome.
Acta Neuropathol **77**:21-25.
- 54) Plassman BL, Williams JW, Jr., Burke JR, Holsinger T, Benjamin S (2010)
Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life.
Ann Intern Med **153**:182-193.
- 55) Daviglus ML, Plassman BL, Pirzada A, et al.
(2011) Risk factors and preventive interventions for Alzheimer disease: state of the science.
Arch Neurol **68**:1185-1190.

- 56) Kokmen E, Beard CM, O'Brien PC, Kurland LT
(1996) Epidemiology of dementia in Rochester, Minnesota.
Mayo Clin Proc **71**:275-282.
- 57) O'Meara ES, Kukull WA, Schellenberg GD, et al.
(1997) Alzheimer's disease and history of blood transfusion by apolipoprotein-E genotype.
Neuroepidemiology **16**:86-93.
- 58) Bohnen NI, Warner MA, Kokmen E, Beard CM, Kurland LT
(1994) Prior blood transfusions and Alzheimer's disease.
Neurology **44**:1159-1160.
- 59) Darby SC, Kan SW, Spooner RJ, et al.
(2007) Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.
Blood **110**:815-825.
- 60) Maarouf CL, Dausgs ID, Kokjohn TA, et al.
(2011) Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging.
PLoS ONE **6**:e27291.
- 61) Huang Y, Halliday G
(2013) Can we clinically diagnose dementia with Lewy bodies yet?
Transl Neurodegener **2**:4.
- 62) Notari S, Moleris FJ, Hunter SB, et al.
(2010) Multiorgan detection and characterization of protease-resistant prion protein in a case of variant CJD examined in the United States.
PLoS ONE **5**:e8765.
- 63) Roeber S, Grasbon-Frodl EM, Windl O, et al.
(2008) Evidence for a pathogenic role of different mutations at codon 188 of PRNP.
PLoS ONE **3**:e2147.
- 64) Anderson VL, Webb WW
(2011) Transmission electron microscopy characterization of fluorescently labelled amyloid beta 1-40 and alpha-synuclein aggregates.
BMC Biotechnol **11**:125.
- 65) Wang JZ, Gong CX, Zaidi T, Grundke-Iqbal I, Iqbal K
(1995) Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B.
J Biol Chem **270**:4854-4860.
- 66) Watts JC, Balachandran A, Westaway D
(2006) The expanding universe of prion diseases.
PLoSPathog **2**:e26.